ERBB2 and breast carcinoma: Improved anti-tumour effects could be achieved by the continuation of treatment of these mice with anti-neu mAb, similar to the therapy in breast cancer patients who often receive anti-Her2 mAb over long periods of time35 or combining it with a tumour targeting agent such as anti-DR5 mAb that induces tumour cell death directly11.